Altimmune, Inc. (ALT) stock
ALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.53−0.03 (-1.92%)
Close on Nov 17, 2026Market cap $297.61MP/E –Yield –
Altimmune revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Altimmune's revenue for the twelve months ending Dec 31, 2025 was $41.00K, up 105.0% year over year. For fiscal 2025 it was $41.00K, up 105.0% from the year before. Over ten years it grew -47.2% a year on average. The highest annual figure on record is $24.27M in fiscal 2011.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $41.00K | +105.0% |
| FY2024 | Dec 31, 2024 | $20.00K | -95.3% |
| FY2023 | Dec 31, 2023 | $426.00K | – |
| FY2022 | Dec 31, 2022 | -$68.00K | -101.5% |
| FY2021 | Dec 31, 2021 | $4.41M | -46.1% |
| FY2020 | Dec 31, 2020 | $8.19M | +41.1% |
| FY2019 | Dec 31, 2019 | $5.80M | -43.8% |
| FY2018 | Dec 31, 2018 | $10.33M | -3.8% |
| FY2017 | Dec 31, 2017 | $10.74M | +231.8% |
| FY2016 | Dec 31, 2016 | $3.24M | -86.7% |
| FY2011 | Dec 31, 2011 | $24.27M | +15.6% |
| FY2010 | Dec 31, 2010 | $20.99M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | $26.00K | +420.0% |
| Q3 FY2025 | Sep 30, 2025 | $5.00K | 0.0% |
| Q2 FY2025 | Jun 30, 2025 | $5.00K | 0.0% |
| Q1 FY2025 | Mar 31, 2025 | $5.00K | 0.0% |
| Q4 FY2024 | Dec 31, 2024 | $5.00K | -86.5% |
| Q3 FY2024 | Sep 30, 2024 | $5.00K | -98.6% |
| Q2 FY2024 | Jun 30, 2024 | $5.00K | -16.7% |
| Q1 FY2024 | Mar 31, 2024 | $5.00K | -76.2% |
| Q4 FY2023 | Dec 31, 2023 | $37.00K | +1750.0% |
| Q3 FY2023 | Sep 30, 2023 | $362.00K | +4425.0% |
| Q2 FY2023 | Jun 30, 2023 | $6.00K | -81.3% |
| Q1 FY2023 | Mar 31, 2023 | $21.00K | -99.4% |
| Q3 FY2022 | Sep 30, 2022 | $2.00K | -98.7% |
| Q2 FY2022 | Jun 30, 2022 | $8.00K | -94.2% |
| Q1 FY2022 | Mar 31, 2022 | $32.00K | -96.2% |
| Q4 FY2021 | Dec 31, 2021 | $3.28M | +41.7% |
| Q3 FY2021 | Sep 30, 2021 | $158.00K | -94.6% |
| Q2 FY2021 | Jun 30, 2021 | $137.00K | -81.0% |
| Q1 FY2021 | Mar 31, 2021 | $838.00K | -62.1% |
| Q4 FY2020 | Dec 31, 2020 | $2.31M | +301.7% |
| Q3 FY2020 | Sep 30, 2020 | $2.94M | +356.2% |
| Q2 FY2020 | Jun 30, 2020 | $721.64K | -55.6% |
| Q1 FY2020 | Mar 31, 2020 | $2.21M | -25.1% |
| Q4 FY2019 | Dec 31, 2019 | $575.80K | -77.8% |
| Q3 FY2019 | Sep 30, 2019 | $643.98K | -75.6% |
| Q2 FY2019 | Jun 30, 2019 | $1.63M | -32.7% |
| Q1 FY2019 | Mar 31, 2019 | $2.96M | +9.8% |
| Q4 FY2018 | Dec 31, 2018 | $2.59M | -7.8% |
| Q3 FY2018 | Sep 30, 2018 | $2.63M | -42.6% |
| Q2 FY2018 | Jun 30, 2018 | $2.42M | -20.4% |
| Q1 FY2018 | Mar 31, 2018 | $2.69M | +798.3% |
| Q4 FY2017 | Dec 31, 2017 | $2.81M | +159.1% |
| Q3 FY2017 | Sep 30, 2017 | $4.59M | +409.6% |
| Q2 FY2017 | Jun 30, 2017 | $3.04M | – |
| Q1 FY2017 | Mar 31, 2017 | $299.57K | – |
| Q4 FY2016 | Dec 31, 2016 | $1.08M | – |
| Q3 FY2016 | Sep 30, 2016 | $901.04K | – |
See a number that looks wrong?